Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia – a review of its characteristics

BACKGROUND: The purpose of this study was to review the current literature and information on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the US Food and Drug Administration in October 2011. METHODS: PubMed (2001–2014) was searched for primary and review arti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramadan, Wijdan H, Kabbara, Wissam K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334171/
https://www.ncbi.nlm.nih.gov/pubmed/25709467
http://dx.doi.org/10.2147/VHRM.S79198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334171/
https://www.ncbi.nlm.nih.gov/pubmed/25709467
http://dx.doi.org/10.2147/VHRM.S79198

Ejemplares similares